Cargando…

Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?

In recent years, scientists have advocated the use of targeted therapies in the form of drugs that modulate genes and proteins that are directly associated with cancer progression and metastasis. Malignant melanoma is a dreadful cancer type that has been associated with the rapid dissemination of pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prasad, Chandra Prakash, Mohapatra, Purusottam, Andersson, Tommy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586801/ https://www.ncbi.nlm.nih.gov/pubmed/26393652 http://dx.doi.org/10.3390/cancers7030868

Ejemplares similares

WNT5A as a therapeutic target in breast cancer
por: Prasad, Chandra Prakash, et al.
Publicado: (2018)

Combination therapy targeting the elevated interleukin‐6 level reduces invasive migration of BRAF inhibitor‐resistant melanoma cells
por: Mohapatra, Purusottam, et al.
Publicado: (2019)

Demonstration of a WNT5A-IL-6 positive feedback loop in melanoma cells: Dual interference of this loop more effectively impairs melanoma cell invasion
por: Linnskog, Rickard, et al.
Publicado: (2016)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

WNT5A-Induced Activation of the Protein Kinase C Substrate MARCKS Is Required for Melanoma Cell Invasion
por: Mohapatra, Purusottam, et al.
Publicado: (2020)

Increased MARCKS Activity in BRAF Inhibitor-Resistant Melanoma Cells Is Essential for Their Enhanced Metastatic Behavior Independent of Elevated WNT5A and IL-6 Signaling
por: Yadav, Vikas, et al.
Publicado: (2022)

Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells
por: Reddi, Kiran Kumar, et al.
Publicado: (2022)

The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma
por: Thompson, Elizabeth L., et al.
Publicado: (2021)

Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells
por: Li, Bohui, et al.
Publicado: (2021)

The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
por: Paris, Anaïs, et al.
Publicado: (2022)

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
por: Krayem, Mohammad, et al.
Publicado: (2018)

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells
por: Fratangelo, Federica, et al.
Publicado: (2018)

Harnessing host innate immunity may combat acquired resistance to BRAFi
por: Tan, Thomas, et al.
Publicado: (2014)

Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion
por: Prasad, Chandra Prakash, et al.
Publicado: (2017)

BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma
por: Gebhardt, Kathleen, et al.
Publicado: (2021)

miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma
por: Stark, Mitchell S., et al.
Publicado: (2015)

Interleukin‐6 drives melanoma cell motility through p38α‐MAPK‐dependent up‐regulation of WNT5A expression
por: Linnskog, Rickard, et al.
Publicado: (2014)

WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition
por: Prasad, Chandra Prakash, et al.
Publicado: (2016)

WNT‐5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells
por: Prasad, Chandra Prakash, et al.
Publicado: (2013)

Reduced WNT5A signaling in melanoma cells favors an amoeboid mode of invasion
por: Jobe, Njainday Pulo, et al.
Publicado: (2021)

Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model
por: Canesin, Giacomo, et al.
Publicado: (2017)

miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways
por: Sun, Xiaoyan, et al.
Publicado: (2016)

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
por: Rogala, Paweł, et al.
Publicado: (2022)

2-Methoxyestradiol-3,17-O,O-bis-sulfamate (STX140) Inhibits Proliferation and Invasion via Senescence Pathway Induction in Human BRAFi-Resistant Melanoma Cells
por: Franco, Ylana Adami, et al.
Publicado: (2023)

Differentiation of the brain vasculature: the answer came blowing by the Wnt
por: Liebner, Stefan, et al.
Publicado: (2010)

Molecular regulation of kidney development: is the answer blowing in the Wnt?
por: Merkel, Calli E., et al.
Publicado: (2007)

WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells
por: Ekström, Elin J, et al.
Publicado: (2014)

WNT Signaling in Melanoma
por: Gajos-Michniewicz, Anna, et al.
Publicado: (2020)

Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
por: Fenton, Sarah E., et al.
Publicado: (2019)

RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy
por: Radaszkiewicz, Tomasz, et al.
Publicado: (2021)

LGR5 Expression Predicting Poor Prognosis Is Negatively Correlated with WNT5A in Colon Cancer
por: Mehdawi, Lubna M., et al.
Publicado: (2023)

WNT5A Signaling Contributes to Aβ-Induced Neuroinflammation and Neurotoxicity
por: Li, Bei, et al.
Publicado: (2011)

Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells
por: Leandersson, Karin, et al.
Publicado: (2006)

Higher expression of WNT5A protein in oral squamous cell carcinoma compared with dysplasia and oral mucosa with a normal appearance
por: Prgomet, Zdenka, et al.
Publicado: (2017)

The Prognostic Significance of Wnt-5a Expression in Primary Breast Cancer Is Extended to Premenopausal Women
por: Sand-Dejmek, Janna, et al.
Publicado: (2013)

Deliberate self-harm and domestic violence: Some answers needed
por: Prakash, Om, et al.
Publicado: (2011)

Targeted Therapy in Melanoma and Mechanisms of Resistance
por: Czarnecka, Anna M., et al.
Publicado: (2020)

Resistance to Molecularly Targeted Therapies in Melanoma
por: Patel, Meet, et al.
Publicado: (2021)

PAK1 and Therapy Resistance in Melanoma
por: Kichina, Julia V., et al.
Publicado: (2023)

In the Wnt-er of life: Wnt signalling in melanoma and ageing
por: Kaur, Amanpreet, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i4p74jup1a8s2i4bgamjh507sh